NCT06821061: An ongoing trial by Biontech SE
This trial is ongoing. It must report results 1 year from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06821061 |
|---|---|
| Title | A PHASE 1/2 RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 10, 2025 |
| Completion date | Dec. 22, 2025 |
| Required reporting date | Dec. 22, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |